Kindred Biosciences, Inc. (KIN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.25+0.23 (+5.72%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close4.02
Bid4.24 x 800
Ask4.25 x 200
Day's Range4.20 - 4.38
52wk Range2.90 - 6.38
1y Target EstN/A
Market Cap84.31M
P/E Ratio (ttm)-3.44
Avg Vol (3m)20,839
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA

    SAN FRANCISCO, Aug. 22, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of KIN earnings conference call or presentation 8-Aug-16 8:30pm GMT

    Q2 2016 Kindred Biosciences Inc Earnings Call

  • Associated Press16 days ago

    Kindred Bio reports 2Q loss

    On a per-share basis, the Burlingame, California-based company said it had a loss of 25 cents. In the final minutes of trading on Monday, the company's shares hit $3.96. A year ago, they were trading at ...